2017-03-24,Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
2017-03-02,Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2017-02-23,Sage Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update
2017-02-17,Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
2017-02-17,Sage Therapeutics To Report Fourth Quarter And Full Year 2016 Financial Results On Thursday, February 23, 2017
2017-02-16,Sage Therapeutics Not In M&A Discussions: STATEMENT
2017-02-13,Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data
2017-02-13,Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics
2017-02-13,Sage Therapeutics Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder
2017-02-07,Sage Therapeutics To Participate In Upcoming February Investor Conferences
2017-01-03,Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017
2017-01-03,17 Thoughts on Biotech Stocks to Kick Off 2017
2017-01-02,Starbucks, Allergan, Amazon: Doug Kass' Views
2016-12-29,Sage Therapeutics To Participate In Goldman Sachs Healthcare Conference
2016-12-19,Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Mood Disorders
2016-12-19,Allergan, Apple, Oakland Capital: Doug Kass' Views
2016-12-13,Sage Therapeutics Announces Initiation Of Phase 2 Clinical Development For SAGE-217 In Movement Disorders
2016-12-12,Facebook, Apple, Starbucks: Doug Kass' Views
2016-12-07,Sage Therapeutics To Webcast R&D Day On December 13, 2016
2016-12-06,Sage Announces Expedited Development Plan For SAGE-547 In The Treatment Of Postpartum Depression Based On FDA Breakthrough Therapy Meeting
2016-12-05,Apple, Starbucks, Cisco: Doug Kass' Views
2016-12-01,Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting
2016-11-28,Home Depot, Lowe's, Best Buy: Doug Kass' Views
2016-11-25,Apple Continues to Underperform; the Market Is Resistant: Best of Kass
2016-11-21,Facebook, Home Depot, Disney: Doug Kass' Views
2016-11-16,SAGE-547 Granted PRIME Designation By EMA For The Treatment Of Postpartum Depression
2016-11-14,Allergan, Macy's, Apple: Doug Kass' Views
2016-11-10,Sage Therapeutics To Present At Society For Neuroscience 2016 Annual Meeting
2016-11-09,Sage Therapeutics To Present At The Stifel 2016 Healthcare Conference
2016-11-07,Cisco, Allergan, Facebook: Doug Kass' Views
2016-11-04,Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass
2016-11-03,Sage Therapeutics Announces Third Quarter 2016 Financial Results And Provides SRSE European Update
2016-10-27,Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016
2016-09-27,Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marc√© Society For Perinatal Mental Health Biennial Scientific Meeting
2016-09-21,Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
2016-09-16,Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting
2016-09-08,Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-09-08,'Mad Money' Lightning Round: I Believe in Walt Disney
2016-09-07,Jim Cramer's 'Mad Money' Recap: The Perils of Competition
2016-09-07,Sage Therapeutics Announces Proposed Public Offering Of Common Stock
2016-09-06,Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression
2016-08-30,Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics
2016-08-10,Short Interest In Sage Therapeutics Expands By 12.7%
2016-08-09,SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss
2016-08-09,Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update
2016-08-03,Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-08-02,Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016
2016-07-22,Biogen Should Either a Buyer or a Seller Be
2016-07-19,Sage Appoints Geno Germano To Company's Board Of Directors
2016-07-12,Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results
2016-07-12,SAGE Shares Surge After Postpartum Depression Drug Shows Promise
2016-07-12,Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'
2016-07-12,Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial
2016-07-12,Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression
2016-06-27,A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle
2016-06-27,First Week of SAGE February 2017 Options Trading
2016-06-07,Sage Therapeutics' Approach To GABA Receptor Drug Development
2016-06-01,Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-27,Biotech Stock Mailbag: Sage Therapeutics, Minerva
2016-05-26,Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression
2016-05-24,First Week of SAGE July 15th Options Trading
2016-05-16,Monsanto, Amazon and Apple: Doug Kass' Views
2016-05-05,Sage Therapeutics Announces First Quarter 2016 Financial Results
2016-04-28,Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016
2016-04-17,Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting
2016-04-11,Facebook, Ford and General Motors: Doug Kass' Views
2016-03-28,Sage Therapeutics To Present Data At The Society Of Biological Psychiatry 71st Annual Scientific Meeting
2016-03-24,First Week of SAGE November 18th Options Trading
2016-03-23,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Sage Therapeutics, Inc. - SAGE
2016-03-23,EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE
2016-03-23,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Sage Therapeutics, Inc. (SAGE)
2016-03-23,Here&rsquo;s Why Sage Therapeutics (SAGE) Stock is Tumbling Today
2016-03-07,Tesla, Amazon and Netflix: Doug Kass' Views
2016-03-03,Sage Therapeutics To Present SAGE-547 Clinical Data And SRSE Health Economic Data In Five Abstracts At The American Academy Of Neurology 2016 Annual Meeting
2016-02-29,Sage Therapeutics To Present At The Cowen & Co. 36th Annual Health Care Conference
2016-02-24,Sage Therapeutics Announces Fourth Quarter And Full Year 2015 Financial Results
2016-02-19,What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
2016-02-17,Sage Therapeutics To Report Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 24, 2016
2016-02-15,JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views
2016-02-15,General Motors, MetLife and Tesla: Doug Kass' Views
2016-02-11,Sage Therapeutics Stock Sees Short Interest Jump 12%
2016-02-03,Sage Therapeutics To Present At The 2016 Leerink Global Healthcare Conference
2016-02-01,Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?
2016-01-06,Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock
2016-01-05,Sage Therapeutics Announces Proposed Public Offering Of Common Stock
2016-01-04,Sage Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference
2015-12-15,SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547
2015-12-02,SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting
2015-11-24,SAGE To Present At The Piper Jaffray 27th Annual Healthcare Conference
2015-11-05,SAGE Announces Third Quarter 2015 Financial Results And Recent Pipeline Progress
2015-11-03,SAGE Announces Presentations At Upcoming November Investor Conferences
2015-10-29,SAGE To Report Third Quarter 2015 Financial Results On Thursday, November 5, 2015
2015-10-08,SAGE To Present Data At Upcoming Scientific Conferences
2015-10-06,SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217
2015-09-23,SAGE Therapeutics To Participate In The 4th Annual Leerink Partners Rare Disease Roundtable
2015-09-21,SAGE Therapeutics Expands Leadership Team With Key Appointments
2015-09-03,Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study
2015-09-03,SAGE Therapeutics Announces Results From Successful Exploratory Trial In Essential Tremor
2015-08-17,SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-08-12,SAGE Therapeutics Announces Second Quarter 2015 Financial Results And Highlights Recent Progress
2015-08-06,SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-08-05,SAGE Therapeutics To Present At The Canaccord Genuity 35th Annual Growth Conference
2015-06-09,SAGE Therapeutics Announces Positive Top-Line Data In Exploratory Trial Of SAGE-547 In Postpartum Depression
2015-06-03,Where the Money Was Made the Last 5 Years
2015-06-03,SAGE Therapeutics To Participate In The Goldman Sachs 36th Annual Global Healthcare Conference
2015-05-14,SAGE Therapeutics Announces SAGE-547 Progress And First Quarter 2015 Financial Results
2015-05-14,SAGE Therapeutics Achieves 77 Percent Response Rate In Completed Phase 1/2 Clinical Trial Of SAGE-547 In Super-Refractory Status Epilepticus
2015-05-12,SAGE Therapeutics To Present At UBS Global Healthcare Conference
2015-05-07,SAGE Therapeutics To Report First Quarter 2015 Financial Results On Thursday, May 14
2015-04-21,SAGE Therapeutics Announces Closing Of $138 Million Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares
2015-04-20,SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus
2015-04-14,SAGE Therapeutics Announces Pricing Of Public Offering Of Common Stock
2015-04-13,SAGE Therapeutics Announces Proposed Public Offering Of Common Stock
2015-04-09,SAGE Therapeutics Announces Presentations At Upcoming Scientific Conferences
2015-04-02,SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015
2015-02-27,SAGE Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results
2015-02-13,SAGE Therapeutics Appoints New Vice Presidents To Lead Key Organizational Functions
2015-01-28,SAGE Therapeutics Announces Participation In February Conferences
2015-01-12,SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression
2015-01-09,SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
2015-01-05,SAGE Therapeutics To Present At 33rd Annual J.P. Morgan Healthcare Conference
2014-12-17,SAGE Therapeutics Added To NASDAQ Biotechnology Index
2014-11-11,SAGE Therapeutics Reports Third Quarter 2014 Results
2014-11-10,SAGE Therapeutics Reports Positive Top-Line Phase 2 Data Of SAGE-547 In Patients With Super-Refractory Status Epilepticus
2014-11-10,Severe Epileptic Patients in Coma Respond to Sage Therapeutics Experimental Drug
2014-11-07,SAGE Therapeutics Announces Six Scientific Presentations At Neuroscience 2014, The Society For Neuroscience's 44th Annual Meeting
2014-11-05,SAGE To Present At Credit Suisse 23rd Annual Healthcare Conference
2014-11-03,First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology
2014-10-23,SAGE Therapeutics Initiates Exploratory Study Of SAGE-547 In Essential Tremor
2014-09-25,SAGE Therapeutics To Participate In The 2014 Leerink Partners Rare Disease Roundtable
2014-09-16,SAGE Therapeutics Appoints Michael F. Cola To The Company's Board Of Directors
2014-09-02,SAGE Therapeutics Presents New Preclinical Data On SAGE-217 At Eilat Conference On New Anti-Epileptic Drugs
2014-08-14,SAGE Therapeutics Reports Second Quarter 2014 Financial Results
2014-08-07,SAGE Therapeutics To Present At Canaccord Genuity 34th Annual Growth Conference
2014-07-23,SAGE Therapeutics Announces Closing Of Initial Public Offering
2014-07-22,SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus
2014-07-21,SAGE Therapeutics Announces Full Exercise Of Over-Allotment Option
2014-07-18,Sage Therapeutics (SAGE) Stock Soars on First Trading Day After IPO
,
